Oxoglaucine
Oxoglaucine (O-Methylatheroline) is a natural product with multiple activities including autophagy activation, anti-inflammation, antibacterial activity, and immunoregulation. Oxoglaucine inhibits the TRPV5/calmodulin/CAMK-II pathway, suppresses TGFβ-induced Smad2 phosphorylation by upregulating Smad7, blocks Ca2+ influx, activates autophagy, alleviates apoptosis and inflammation, inhibits ROS production and the expression of fibrosis markers in hepatocytes, and regulates immune cell populations and responses. Oxoglaucine protects against infections caused by Candida albicans and Klebsiella pneumoniae, and exerts effects on adjuvant-induced arthritis. Oxoglaucine can be used in studies related to arthritis, liver fibrosis, bacterial infections, and fungal infections.
For research use only. We do not sell to patients.
- CAS No.: 5574-24-3
- Formula: C20H17NO5
- Molecular Weight:351.35
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Caspase Isoforms
More
Biological Activity
Description
|
TRPC5 |
CaMK II |
IL-6 |
Collagen I |
Caspase 3 |
TNF-α |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | CC50 |
51 μM
Compound: Oxoglaucine
|
Antiviral activity against Human rhinovirus type 14 in human HeLa Ohio-1 cells
Antiviral activity against Human rhinovirus type 14 in human HeLa Ohio-1 cells
|
[PMID: 18590964] |
| HeLa | IC50 |
0.3 μM
Compound: Oxoglaucine
|
Cytotoxicity against human HeLa Ohio-1 cells
Cytotoxicity against human HeLa Ohio-1 cells
|
[PMID: 18590964] |
| RAW264.7 | IC50 |
50 μM
Compound: 13
|
Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
|
[PMID: 33939429] |
| RAW264.7 | IC50 |
>50 μM
Compound: 13
|
Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
|
[PMID: 33939429] |
In Vitro
Oxoglaucine (1.25-40 ng/mL; 24 h) enhances the viability and proliferation of human osteoarthritic chondrocytes, while higher concentrations reduce their viability[1].
Oxoglaucine (10-40 ng/mL; 24 h) exerts a protective effect on human osteoarthritic chondrocytes by enhancing cell viability; it promotes cartilage matrix maintenance in human osteoarthritic chondrocytes by increasing GAG secretion and upregulating the mRNA expression of cartilage-specific markers Sox-9, Aggrecan and Col 2A1[1].
Oxoglaucine (10-40 ng/mL; 24 h) reduces Ca2+ influx in human osteoarthritic chondrocytes and downregulates the TRPV5/calmodulin/CAMK-II pathway in these cells[1].
Oxoglaucine (10-15 μM; 24 h pretreatment, 6 h TGFβ stimulation) inhibits TGFβ-induced phosphorylation of Smad2 in Hepa1c1c7 cells and primary mouse hepatocytes, and additionally reduces TGFβ-induced phosphorylation of AKT in primary mouse hepatocytes. It suppresses the expression of fibrosis-related genes (collagen type I alpha 1 chain, α-SMA, fibronectin) and the corresponding protein (collagen type I alpha 1 chain), and inhibits the expression of IL6 and Ccl2[2].
Oxoglaucine (10-15 μM; 24 h pretreatment, 6 h TGFβ stimulation) inhibits TGFβ-induced expression of fibrosis markers in human LX-2 hepatic stellate cells[2].
Oxoglaucine (10-40 ng/mL; 24 h) alleviates inflammation and apoptosis in human osteoarthritic chondrocytes by downregulating the mRNA and protein expression of inflammatory, apoptotic and catabolic markers, as well as reducing the levels of NO, PGE2 and ADAMTS-5; it activates autophagy in human osteoarthritic chondrocytes by upregulating the mRNA and protein expression of autophagy-related markers LC3, Beclin-1, ATG5 and ATG7[1].
Oxoglaucine (10 μM; pre-treatment for 24 h followed by TGFβ stimulation) inhibits TGFβ-induced ROS production and upregulates Smad7 expression in Hepa1c1c7 cells[2].
Oxoglaucine (40 ng/mL; 24 h) activates autophagy in human osteoarthritic chondrocytes by increasing the formation of autolysosomes and promoting acidification[1].
Oxoglaucine (2×10-4 M; 72 h) inhibits mitogen-induced proliferation of mouse splenocytes[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human osteoarthritis (OA) chondrocytes
-
Concentration:1.25, 2.50, 5.00, 10.00, 20.00, 40.00, 80.00, 160.00 ng/mL
-
Incubation Time:24 h
-
Result:Increased cell viability/proliferation significantly at 1.25-40 ng/mL.
Reduced cell viability significantly at 80 ng/mL and 160 ng/mL.
-
Cell Line:human osteoarthritis (OA) chondrocytes
-
Concentration:10, 20, 40 ng/mL
-
Incubation Time:24 h
-
Result:Increased the number of viable green-stained cells significantly and decreased the number of dead red-stained cells significantly compared to untreated control.
-
Cell Line:human osteoarthritis (OA) chondrocytes
-
Concentration:10, 20, 40 ng/mL
-
Incubation Time:24 h
-
Result:Up-regulated mRNA expression of Sox-9, Aggrecan, and Col 2A1 significantly compared to untreated control.\nDown-regulated mRNA expression of IL-6, IL-1β, TNF-α, MMP-13, CASP-3, and BAX significantly.
Up-regulated mRNA expression of LC3, Beclin-1, ATG5, and ATG7 significantly.
-
Cell Line:human osteoarthritis (OA) chondrocytes
-
Concentration:10, 20, 40 ng/mL
-
Incubation Time:24 h
-
Result:Reduced PGE2 and ADAMTS-5 levels significantly compared to untreated control.
-
Cell Line:human osteoarthritis (OA) chondrocytes
-
Concentration:10, 20, 40 ng/mL
-
Incubation Time:24 h
-
Result:Down-regulated protein expression of COX-2, iNOS, IL-6, IL-1β, TNF-α, MMP-13, CASP-3, and BAX significantly in a dose-dependent manner compared to untreated control.\nUp-regulated protein expression of LC3, Beclin-1, ATG5, and ATG7 significantly compared to untreated control.
-
Cell Line:human osteoarthritis (OA) chondrocytes
-
Concentration:40 ng/mL
40 ng/mL plus 10-8 mol/L D3 -
Incubation Time:24 h
-
Result:Decreased protein expression of TRPV5, calmodulin, and CAMK-II significantly at 40 ng/mL.
Reversed the down-regulatory effect on TRPV5, calmodulin, and CAMK-II when co-treated with D3.
-
Cell Line:human osteoarthritis (OA) chondrocytes
-
Concentration:10, 20, 40 ng/mL
-
Incubation Time:24 h
-
Result:Increased Cyto-ID Green fluorescence intensity dose-dependently, indicating enhanced autophagy activity.
-
Cell Line:murine Hepa1c1c7 hepatoma cells
-
Concentration:1, 5, 10, 15, 30 μM (viability assay)
10, 15 μM (apoptosis and cleaved caspase-3 analysis) -
Incubation Time:24 h
-
Result:Did not significantly reduce cell viability at concentrations up to 15 μM.
Significantly reduced cell viability at 30 μM.
Showed no changes in cell number or morphology after 24 h exposure to 10 μM.
Did not increase apoptotic cell percentage at 10 and 15 μM compared to vehicle control.
Did not increase cleaved caspase-3 levels at 10 μM.
-
Cell Line:murine Hepa1c1c7 hepatoma cells, primary mouse hepatocytes
-
Concentration:10, 15 μM
-
Incubation Time:24 h pretreatment, followed by 6 h TGFβ stimulation
-
Result:Reduced TGFβ-induced Smad2 phosphorylation by approximately 40% in Hepa1c1c7 cells without altering total Smad2 levels.
Did not change TGFβ-induced AKT phosphorylation in Hepa1c1c7 cells.
Did not affect ERK phosphorylation in Hepa1c1c7 cells.
Attenuated TGFβ-induced Smad2 phosphorylation in primary mouse hepatocytes.
Significantly decreased TGFβ-induced AKT phosphorylation in primary mouse hepatocytes.
-
Cell Line:murine Hepa1c1c7 hepatoma cells, primary mouse hepatocytes
-
Concentration:10, 15 μM
-
Incubation Time:24 h pretreatment, followed by 6 h TGFβ stimulation
-
Result:Reduced TGFβ-induced transcript levels of collagen type 1 alpha 1, α-SMA, and fibronectin in Hepa1c1c7 cells.
Did not affect Timp1 mRNA levels in Hepa1c1c7 cells.
Reduced TGFβ-induced transcript levels of collagen type 1 alpha 1, α-SMA, and fibronectin in primary mouse hepatocytes.
Significantly inhibited TGFβ-induced collagen type 1 alpha 1 protein expression in primary mouse hepatocytes.
Altered α-SMA mRNA levels when used alone, but did not affect Smad2 phosphorylation or other fibrogenic marker mRNA levels alone.
-
Cell Line:murine Hepa1c1c7 hepatoma cells, primary mouse hepatocytes
-
Concentration:10 μM (Hepa1c1c7 cells)
15 μM (primary mouse hepatocytes) -
Incubation Time:24 h pretreatment, followed by 6 h TGFβ stimulation
-
Result:Reduced TGFβ-induced Il6 and Ccl2 mRNA levels in Hepa1c1c7 cells.
Did not change Tnf-alpha mRNA levels in Hepa1c1c7 cells.
Reduced TGFβ-induced IL6 mRNA levels in primary mouse hepatocytes.
Did not affect Ccl2 and Tnf-alpha mRNA levels in primary mouse hepatocytes.
In Vivo
Oxoglaucine (0.02-5.0 mg/kg; i.p.; single administration; daily) regulates antibody-mediated immune responses in a dose-dependent and regimen-dependent manner. Among the tested regimens, the daily administration of 0.5 mg/kg for 3 consecutive days prior to immunization with sheep red blood cells (SRBC) exerts the strongest inhibitory effect on anti-SRBC IgM[4].
Oxoglaucine (0.5 mg/kg; i.p.; administered on day 0 and day +2) significantly enhances SRBC-induced PLN responses[4].
Oxoglaucine (0.5 mg/kg; i.p.; once daily for 5 consecutive days) enhances LPS-induced B cell activation and increases anti-LPS IgM levels[4].
Oxoglaucine (1 mg/kg; i.p.; daily) modulates adjuvant-induced arthritis depending on the timing of treatment: it exacerbates paw swelling in the early stage of the disease and reduces swelling in the established disease stage[4].
Oxoglaucine (1-20 mg/kg; i.p.; daily administration for 3 consecutive days before inoculation; single administration on day 0; single administration 24 h before inoculation) dose-dependently enhances resistance to Klebsiella pneumoniae infection[4].
Oxoglaucine (10 mg/kg; i.p.; once daily; for 10 consecutive days) modulates splenic lymphocyte subsets in adult female ICR mice infected with Candida albicans, inhibits the accumulation of serum TNF-α, significantly reduces CD4+ cells, and prevents the infection-induced increase in CD8+ and Ig+ cells[5].
Oxoglaucine (5 mg/kg; i.p.; once daily for 3 consecutive days) reduces the numbers of splenic CD4+, CD8+ and Ig+ cell populations when detected at 8 weeks post Candida albicans infection[5].
Oxoglaucine (10 mg/kg, intraperitoneal injection, once daily for 10 consecutive days) suppresses late-stage serum TNF-α accumulation and elevates host resistance to Candida albicans infection in female ICR mice with adjuvant-induced arthritis[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 7 weeks old, 250-280 g, destabilization of the medial meniscus surgical induction)[1]
-
Dosage:40 ng/mL
-
Administration:intra-articular; twice weekly; 4 weeks
-
Result:Cut macroscopic cartilage wear and macroscopic scores by half.
Presented slight cartilage destruction and proteoglycan loss with lower OARSI scores than OA+PBS and OA+HA groups.
Suppressed synovial TNF-α, IL-6, caspase-3 and BAX levels.
Dropped cartilage TRPV5, TNF-α and MMP-13 protein expression.
Raised cartilage Beclin-1 expression and LC3-II/LC3-I ratio.
-
Animal Model:ICR mice (male, 7-10 weeks old, 18-20 g body weight)[4]
-
Dosage:0.02 mg/kg; 0.05 mg/kg; 0.25 mg/kg; 0.5 mg/kg; 5.0 mg/kg
-
Administration:i.p.; single dose; daily on Days −3, −2, −1; daily on Days 0, +1, +2; daily on Days +1, +2, +3, +4; daily on Days −3, −2, −1, 0, +1, +2, +3, +4
-
Result:Cut in vitro anti-SRBC PFC counts at single 0.25 mg/kg and 0.5 mg/kg doses.
Dropped anti-SRBC IgM hemagglutination titers to 4.7 (0.5 mg/kg) and 5.2 (5.0 mg/kg) with Days -3, -2, -1 pre-immunization dosing, versus control titer 8.4.
Produced maximal anti-SRBC IgM titer suppression (4.7) via repeated 0.5 mg/kg Days -3, -2, -1 dosing; lowered titers to 5.6 with Days 0, +1, +2 dosing, but lifted titers to 10.0 with Days +1 to +4 dosing.
Slumped anti-LPS IgM OD492 to 0.307 (Days -3, -2, -1 repeated 0.5 mg/kg), 0.223 (Days 0, +1, +2) and 0.360 (Days +1 to +4); exerted no impact from single Day 0 dosing.
-
Animal Model:ICR mice (male, 7-10 weeks old, 18-20 g body weight)[4]
-
Dosage:0.5 mg/kg
-
Administration:i.p.; on Day 0 and Day +2
-
Result:Increased the PLN index to 3.4 compared to the control index of 2.9.
Did not alter lymph node weight when administered alone.
-
Animal Model:ICR mice (male, 7-10 weeks old, 18-20 g body weight)[4]
-
Dosage:0.5 mg/kg
-
Administration:i.p.; daily from Day -3 to Day +1
-
Result:Elevated serum anti-LPS IgM OD492 to 0.710 and IgG OD492 to 0.584, versus control 0.576 (IgM) and 0.360 (IgG).
Boosted spleen weight to 340 mg against control 260 mg.
-
Animal Model:ICR mice (male, 7-10 weeks old, 18-20 g body weight)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; daily on Days −7, −6, −5; daily from Day 0 to Day 14; daily from Day 7 to Day 14; daily from Day 14 to Day 21
-
Result:Raised Day 14 paw swelling after dosing on Days -7, -6, -5 or Day 0-14.
Raised Day 28 paw swelling after dosing on Day 7-14.
Lessened Day 28 paw swelling after dosing on Day 14-21.
-
Animal Model:ICR mice (male, 7-10 weeks old, 18-20 g body weight)[4]
-
Dosage:1 mg/kg; 2 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.p.; daily on Days -7, -6, -5; single dose on Day 0; single dose 24 h pre-inoculation
-
Result:Elevated primary inoculation survival to 80% (MST=12.0, control: 50%, MST=9.6) and secondary inoculation survival to 68.75% (MST=10.2, control: 30%, MST=5.7) via daily 1 mg/kg dosing on Days -7, -6, -5.
Boosted primary inoculation survival to 80% (MST=11.7) with no obvious improvement on secondary inoculation survival via single 2 mg/kg dosing on Day 0.
Cut survival down to 12.5% (MST=4.5, control:75%, MST=11.5) via 10 mg/kg administration 24 h before inoculation.
Dropped all survival to 0% (MST=4.5) via 20 mg/kg administration 24 h before inoculation.
Chemical Information
-
CAS No. 5574-24-3
-
Appearance Solid
-
Molecular Weight 351.35
-
Formula C20H17NO5
-
Color Brown to black
-
SMILES
O=C1C2=CC(OC)=C(OC)C=C2C3=C(OC)C(OC)=CC4=CC=NC1=C43
-
Synonyms
O-Methylatheroline
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
-
Liver Histomorphometry
Liver histomorphometry is a quantitative histological approach used to measure structural alterations in hepatic tissue, including parenchymal loss, steatosis, fibrosis, and vascular remodeling, by combining stained tissue section analysis with stereological or computerized image-based measurements. Classical morphometric frameworks quantify volume fractions of liver compartments and fibrotic regions using systematic sampling and image analysis, enabling objective comparison of pathological changes across experimental groups. These approaches are widely applied in liver cirrhosis and fibrosis studies to reduce subjectivity in histological scoring and improve reproducibility of tissue evaluation. Recent methodological advances integrate automated image analysis and radiomics-based extraction of histological features from standard liver stains (e. g. , H&E and fibrotic stains), enabling quantitative correlation between morphometric features and fibrosis stages in non-alcoholic fatty live
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (326 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhong G, et al. Oxoglaucine mediates Ca influx and activates autophagy to alleviate osteoarthritis through the TRPV5/calmodulin/CAMK-II pathway. British journal of pharmacology. 2021 Aug;178(15):2931-2947. [Content Brief]
[2]. Azamov B, et al. Oxoglaucine Suppresses Hepatic Fibrosis by Inhibiting TGFβ-Induced Smad2 Phosphorylation and ROS Generation. Molecules (Basel, Switzerland). 2023 Jun 24;28(13):4971. [Content Brief]
[3]. Harrigan GG, et al. Isolation of bioactive and other oxoaporphine alkaloids from two annonaceous plants, Xylopia aethiopica and Miliusa cf. banacea. Journal of natural products. 1994 Jan;57(1):68-73. [Content Brief]
[4]. Ivanovska N, et al. Immunopharmacological activity of aporphinoid alkaloid oxoglaucine. Pharmacological research. 1997 Apr;35(4):267-72. [Content Brief]
[5]. Ivanovska N, et al. Treatment with oxoglaucine can enhance host resistance to Candida albicans infection of mice with adjuvant arthritis. Diagnostic microbiology and infectious disease. 2000 Sep;38(1):17-20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Oxoglaucine
- 5574-24-3
- O-Methylatheroline
- NO Synthase
- PGE synthase
- TRP Channel
- CaMK
- Calmodulin
- TGF-beta/Smad
- Collagen
- Interleukin Related
- Akt
- TNF Receptor
- Caspase
- Bacterial
- Fungal
- Reactive Oxygen Species (ROS)
- Apoptosis
- Autophagy
- human LX-2 hepatic stellate cells
- autophagy
- primary mouse hepatocytes
- Sprague-Dawley rats
- Klebsiella pneumoniae
- TRPV5
- Hepa1c1c7 cells
- Candida albicans
- human OA chondrocytes
- Smad2
- Inhibitor
- inhibitor
- inhibit